0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD30

CD30

Brief Information

Name:Tumor necrosis factor receptor superfamily member 8
Target Synonym:CD30,CD30L receptor,TNFRSF8,Lymphocyte activation antigen CD30,TNF Receptor Superfamily Member 8,D1S166E,Tumor Necrosis Factor Receptor Superfamily, Member 8,Cytokine Receptor CD30,CD30 Antigen,Ki-1,Ki-1 Antigen,Tumor Necrosis Factor Receptor Superfamily
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD0-HF2H4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD0-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

TN8-H5250-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30, Llama IgG2b Fc Tag, low endotoxin (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD0-H82E6-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human CD30, Avitag,His Tag (Cat. No. CD0-H82E6) on SA Biosensor, can bind Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) with an affinity constant of 139 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

TNFRSF8,CD30,D1S166E,Ki-1

Background

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brentuximab vedotin SGN-30; SGN-35; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE Approved Millennium Pharmaceuticals Inc, Seattle Genetics Inc Adcetris, 安适利 Mainland China Lymphoma, Primary Cutaneous Anaplastic Large Cell; Mycosis Fungoides Bsp Pharmaceuticals Spa 2011-08-19 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Solid tumours; Anemia, Refractory, with Excess of Blasts; Hodgkin Disease; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Sarcoma, Kaposi; Mycosis Fungoides Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EBV-specific-CAR.CD30 EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs Phase 1 Clinical Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System Hodgkin Disease; Lymphoma, Non-Hodgkin Details
TT-11X TT-11X Phase 1 Clinical Tessa Therapeutics Lymphoma Details
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic Details
Anti-CD30 CAR-T cell therapy (National Cancer Institute) Hu30-CD28z Phase 1 Clinical National Cancer Institute Lymphoma Details
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta Phase 2 Clinical Pla General Hospital Hodgkin Disease Details
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) Phase 2 Clinical Unc Lineberger Comprehensive Cancer Center Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin Details
TT-11 Phase 2 Clinical Tessa Therapeutics Hodgkin Disease Details
CD30.CAR H-27721; CD30.CAR Phase 1 Clinical Baylor College Of Medicine Hodgkin Disease; Lymphoma, Non-Hodgkin Details
XmAb-2513 XmAb-2513 Phase 1 Clinical Xencor Hodgkin Disease; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic Details
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Lymphoma, Large B-Cell, Diffuse Details
CD30 CAR-T cell therapy (Tessa Therapeutics) Phase 2 Clinical Tessa Therapeutics Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic Details
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic Details
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral Details
AFM-13 AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Mycosis Fungoides Details

This web search service is supported by Google Inc.

totop